N/A N=115 Study to Compare the Incidence of Biliary Complications After Liver Transplantation
Liver Transplant; Complications
Primary: Number of Participants With Biliary Complications — 19; 12 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Intraoperative Glucose Control in Liver Transplant
Liver Transplant
Primary: Infection Rates — 27; 26; 11; 7 Participants — p=0.841
N/A N=160 The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy
Tissue Donors · Liver Transplantation · Ischemia Reperfusion Injury
Primary: Postopera The Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days — 145; 152 IU/L
Phase 2 N=275 Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Hepatitis C · Hepatitis C, Chronic · Nonimmune Nonviral Causes of Liver Failure
Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants
N/A N=15 Intravenous Interferon During Liver Transplant
Hepatitis C · Cirrhosis
Primary: HCV RNA Result — 924,082; 3,731,749 IU/ml
Phase 4 N=40 Steroid Free Immunosuppression in Liver Transplantation
Liver Cirrhosis · Liver Transplant Disorder
Primary: Graft Survival Rate — 100; 94.7; 90; 84 percentage of participants
Phase 3 N=102 Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics
Liver Transplantation · Surgical Site Infection
Primary: Number of Subjects With Development of Surgical Site Infections — 9; 13 Participants
N/A N=84 Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications
Fatty Liver · Surgery
Primary: Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV) — 1.3; 13.6 Percentage of liver fat content
Phase 4 N=164 Study of Glycemic Control on Liver Transplantation Outcomes
Evidence of Liver Transplantation · Hyperglycemia · Rejection
Primary: Rejection of Liver Transplant — 17; 20 participants — p=0.709
Phase 2 N=25 Human Fetal Liver Cell Transplantation in Chronic Liver Failure
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
N/A N=160 Controlled Attenuation Parameter (CAP) in Liver Allografts
Liver Transplant · Liver Steatosis · Liver Disease
Primary: Controlled Attenuation Parameter (CAP) - Accuracy — 220 dB/m
Phase 4 N=312 Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
End Stage Liver Disease · Hepatitis C
Primary: Freedom From Acute Rejection or HCV Recurrence or Treatment Failure — 69; 70; 133 participants
N/A N=5 Adult Stem Cell Therapy in Liver Insufficiency
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Phase 2 N=93 Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
Reperfusion Injury
Primary: Peak Aspartate Aminotransferase Within First 72h Post Transplant — 1262.9; 1451.2 U/L
Phase 3 N=70 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
N/A N=177 A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Liver Diseases · Hepatocellular Cancer · Endstage Liver Disease
Primary: Living Donor Pain Management — 2.62; 2.56; 2.87; 2.67 Scores on Visual Analogue Pain Scale
Phase 4 N=32 LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients
Hepatitis C
Primary: Treatment Efficacy — 88; 75 % of participants
N/A N=11 Study Evaluating Liver Transplantation in Haemophilia Patients in Spain
Hemophilia · Hemophilia B
Primary: Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation — 7; 6; 4; 3 Participants
N/A N=86 Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
Early Allograft Dysfunction · Ischemic Reperfusion Injury · Liver Transplantation
Primary: Early Allograft Dysfunction — 6; 18 Participants
N/A N=58 Superior Vena Cava and Its Relationship to Central Venous Pressure Measurements in Liver Transplantation
Liver Failure
Primary: Central Venous Pressure (CVP) — 11.7 mmHg
Phase 4 N=174 Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period
Complication, Postoperative
Primary: Complications, Post-anesthesia Care Unit (PACU) — 51; 58 Participants — p=0.213
N/A N=49 Hypothermic Machine Preservation-Phase 2
Liver Damage
Primary: Patient Survival at One Year Post-Transplantation — 19; 19 participants
Phase 4 N=92 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
Hepatitis C · Liver Transplantation
Primary: Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted…
Phase 4 N=71 Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
Asses Immunosuppression Modulation on Renal Recovery Post LT
Primary: Participants Who Have Recovered Renal Function — 28; 20; 11 Participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
N/A N=81 LIFT Intervention in Liver Transplant Candidates
Frailty · Cirrhosis · Liver Transplant
Primary: Frailty — 3.63; 3.48 score on a scale
N/A N=97 Hepatic Vein Flow During Orthotopic Liver Transplantation as Predictive Factor for Postoperative Graft Function
Postoperative Graft Function
Primary: EAD — 1.23; 2.19; 0.87; 1.54 L/kg/min
N/A N=106 Hepatic Effects of Gastric Bypass Surgery
Liver Diseases
Primary: Aspartate Transaminase (AST) Change — -6.32 U/L — p=0.03
Phase 2 N=79 Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Hepatitis C
Primary: Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT) — 0; 5; 6 participants — p=0.0477
Phase 2 N=110 A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
Liver Failure
Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL